Skip to main content
. 2017 Apr 13;8(24):39476–39496. doi: 10.18632/oncotarget.17073

Figure 4. IC50 of cisplatin, oxaliplatin, 5a, 5b and 5c against cisplatin resistant HT29cisR human colon carcinoma cell line (* p < 0.05 compared to cisplatin group).

Figure 4